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A B S T R A C T
Background: Glucocorticoids are widely used in the treatment of several pediatric diseases with undisputed
disease-related beneﬁts. Perinatal exposure to high levels of glucocorticoids can have long-term adverse cerebral
eﬀects. In adults, glucocorticoid treatment has been associated with smaller volumes of subcortical grey matter
structures. Recently, we observed smaller total brain volumes in children and adolescents treated with gluco-
corticoid during childhood compared to healthy controls. The possible long-term eﬀects of glucocorticoid
treatment during childhood on subcortical brain volume and microstructure remain unknown.
Method: We examined 30 children and adolescents, who had previously been treated with glucocorticoids for
nephrotic syndrome or rheumatic disease, and 30 healthy volunteers. Patients and healthy control groups were
matched by age, gender, and level of parent education. Participants underwent 3 T magnetic resonance (MR)
brain imaging. T1-weighted and diﬀusion-weighted images were acquired. Volume and mean diﬀusivity (MD)
measures were extracted for hippocampus, amygdala, nucleus accumbens, caudate nucleus and putamen.
Multiple linear regression analyses were used to assess diﬀerences between patients and controls, and to evaluate
possible dose-response relationships. A priori, we expected patients to display lower hippocampal and amygdala
volumes.
Results: While children previously treated with glucocorticoids displayed smaller right hippocampal volumes
than controls, this diﬀerence did not survive correction for multiple comparisons. Furthermore, patients as
compared to controls showed lower right hippocampal MD, which remained when correcting for global changes
in MD. The longer the time between the glucocorticoid treatment termination and MR-scan, the more right
hippocampal MD values resembled that of healthy controls. Patient and controls did not diﬀer in amygdala
volume or MD. Analyses of the nucleus accumbens, caudate nucleus and putamen only revealed smaller putamen
volumes in patients compared to controls, which remained signiﬁcant when controlling for total brain volume.
Conclusion: The results suggest that extra-cerebral diseases during childhood treated with glucocorticoids may
be associated with reduced subcortical grey matter volumes and lower right hippocampal mean diﬀusivity later
in life. Our ﬁndings warrant replication and elaboration in larger, preferably prospective and longitudinal
studies. Such studies may also allow disentangling disease-speciﬁc eﬀects from possible glucocorticoid treatment
eﬀects.
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1. Introduction
Glucocorticoids have profound anti-inﬂammatory and im-
munosuppressive eﬀects and are successfully used in the treatment of a
number of pediatric diseases (Coutinho and Chapman, 2011; Gravanis
and Margioris, 2001). Along the targeted eﬀects of glucocorticoid
treatment, glucocorticoids can profoundly aﬀect many parts of the
body. Detrimental side-eﬀects on the developing brain have been
identiﬁed (Damsted et al., 2011). In the brain, the eﬀects of gluco-
corticoids are mediated by the mineralocorticoid and glucocorticoid
receptors by both genomic, epigenomic and rapidly induced non-
genomic mechanisms (Gray et al., 2017; Reul and de Kloet, 1985).
Mineralocorticoid receptors are especially abundant in hippocampus
and amygdala, while glucocorticoid receptors are more widely dis-
tributed throughout the human brain (Cao-Lei et al., 2013; de Kloet,
2014; Klok et al., 2011; Reul and de Kloet, 1985). Furthermore, both
hippocampus and amygdala play an important role in regulating en-
dogenous cortisol levels (Dedovic et al., 2009), and are regarded as
cerebral target structures for glucocorticoids (Joels et al., 2009).
The potentially harmful eﬀects of exogenous glucocorticoids in the
brain have so far primarily been studied in relation to exposure peri-
natally or in adulthood. Perinatal exposure to glucocorticoids has been
linked to structural brain changes and neurological and behavioural
problems in oﬀspring later in life, including cortical thinning, cerebral
palsy, abnormal neurological examination and aﬀective problems
(Davis et al., 2013; Doyle et al., 2014; Reynolds, 2013). Furthermore, a
post-mortem study of preterm-born children found that children pre-
natally exposed to glucocorticoids had a lower density of hippocampal
neurons than non-exposed children (Tijsseling et al., 2012), an ob-
servation that is consistent with ﬁndings in animal models (Noorlander
et al., 2008; Uno et al., 1990). Glucocorticoid treatment for extra-cer-
ebral diseases in adulthood has been related to smaller amygdala and
hippocampal volumes measured during treatment (Brown et al., 2004;
Brown et al., 2008). The observed smaller hippocampal volumes may,
at least partially, be due to a lower density of healthy neurons as sug-
gested by lower hippocampal N-acetyl aspartate ratios measured with
magnetic resonance spectroscopy (Brown et al., 2004). Hippocampal
and amygdala atrophy has also been found in adults and children with
elevated levels of endogenous glucocorticoids due to Cushing's disease
(Merke et al., 2005; Patil et al., 2007). Moreover, magnetic resonance
spectroscopy studies in cured Cushing's disease patients revealed lower
hippocampal N-acetyl aspartate and higher glutamate and glutamine
levels suggestive of decreased neuronal density and increased glial
proliferation (Resmini et al., 2013).
While most studies investigated the impact of glucocorticoids on
limbic structures, glucocorticoid treatment may impact other sub-
cortical brain structures as well (Cao-Lei et al., 2013). Notably, ex-
posure to glucocorticoids in the neonatal period has recently been as-
sociated with smaller white matter, putamen, caudate nucleus, and
globus pallidus volumes in adolescents born extremely premature
(< 28weeks), while diﬀerences in hippocampus or amygdala volumes
were not observed (Cheong et al., 2014).
In contrast to pre- and perinatal glucocorticoid exposure, studies
investigating the long-term eﬀects of exogenous glucocorticoid ex-
posure later in childhood are sparse. This is despite the widespread use
of glucocorticoids in the treatment of multiple pediatric diseases
(Damsted et al., 2011), and the fact that the brain continues to mature
throughout childhood and adolescence as evidenced by in vivo mag-
netic resonance imaging (MRI) studies (Brown et al., 2012; Jernigan
et al., 2011; Lebel et al., 2017). Hippocampal and amygdala volumes
increase during late childhood and level oﬀ during adolescence. Cau-
date nucleus, putamen and nucleus accumbens appear to decrease in
volume during late childhood and adolescence into early adulthood
(Ostby et al., 2009; Wierenga et al., 2014). Studies employing diﬀusion-
weighted imaging (DWI) to assess brain tissue microstructure revealed
that subcortical grey matter structures undergo developmental changes,
as indexed by decreasing mean diﬀusivity (MD) (Lebel et al., 2008). MD
reﬂects the magnitude of water diﬀusion and is negatively proportional
to the amount of cell membranes and cellular structures (Beaulieu,
2002). Notably, caudate nucleus MD has been reported to decrease well
into adulthood, while putamen and globus pallidus MD appear to level
oﬀ to adult levels in late adolescence (Lebel et al., 2008). Thus, both
volumetric and microstructural maturation occurs in subcortical re-
gions during childhood and adolescence, which could potentially be
aﬀected by glucocorticoid exposure in this period of life.
The present study aimed to investigate the possible long-term eﬀects
of previous glucocorticoid treatment during childhood on the volume
and microstructure of subcortical grey matter structures. To this end,
we compared child and adolescent patients, previously treated with
glucocorticoids for nephrotic syndrome or rheumatic disease, with
healthy controls. We included these two diﬀerent extra-cerebral pe-
diatric diseases with the aim to control for potential disease-related
eﬀects. In previous work, we observed that these patients had lower
verbal intellectual abilities (Holm et al., 2015) and smaller total brain
volumes as compared to healthy controls (Holm et al., 2018). Fur-
thermore, the children treated with glucocorticoid showed sex-depen-
dent diﬀerences in endogenous cortisol proﬁles compared to healthy
controls, with girls having higher cortisol awakening response (CAR)
and boys having higher cortisol levels during the day (Vestergaard
et al., 2017). In the present study, our primary hypothesis was that
patients, as compared to healthy controls, would have smaller hippo-
campal and amygdala volumes independent of diﬀerences in total brain
volume. Secondary, we expected that patients would diﬀer from con-
trols in hippocampal and amygdala MD. Furthermore, we examined if
patients diﬀered from controls in putamen, caudate nucleus, or nucleus
accumbens volume or MD. Finally, within patients we examined for
possible doses-response associations between glucocorticoid treatment
variables and subcortical brain structure volume or MD.
2. Material and methods
The participants in the present study are the same as in our recent
study investigating the eﬀects on glucocorticoid treatment on global
structural brain measures (Holm et al., 2018). Therefore, if identical,
information on participants, clinical characteristics and background
variables is presented between quotation marks followed by the re-
ference to the previous article.
2.1. Participants
“A total of 30 children and adolescents previously treated with
glucocorticoid because of either rheumatic disease or nephrotic syn-
drome, recruited from outpatient pediatric clinics, and 30 matched
healthy controls, recruited from public schools, were included in the
present study. Patient and control groups were matched on average age,
gender, and parent education. The patients were between 7.0 and 16.1
years of age and consisted of 8 boys and 22 girls. The controls were
between 7.0 and 15.6 years of age and consisted of 11 boys and 19 girls.
The subjects were part of a larger cohort, which has been described in
detail elsewhere (Holm et al., 2018). Of the initial thirty-eight included
patients, seven did not complete MRI scanning and one was excluded
because of poor image quality due to motion artefacts. Thus, 30 patients
with good-quality T1-weighted scans were included in the current
study. Of the initially forty-two included healthy controls, ﬁve parti-
cipants did not complete scanning and one control was excluded be-
cause of motion artefacts. Thus, good-quality scans were available for
36 healthy controls. To ensure that group averages for included patients
were matched to controls on age, gender, and parent education, we
excluded ﬁve boys and one girl with a mean age of 11.8 years and mean
parental education of 17.1 years. Exclusion was done blinded to the
MRI data and before any processing of MRI images or statistical ana-
lyses. There were no signiﬁcant diﬀerences in age, gender, or parental
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education between the initial included subjects and the subjects with
good-quality MRI scan (all P values ≥0.30).
Only children and adolescents without neurological or psychiatric
diseases or preterm birth were included. Controls were required to be
healthy and without previous systemic glucocorticoid treatment. Only
patients without current glucocorticoid treatment at the time of the
study were included. The study was ethically approved by the Scientiﬁc
Ethical Committee, Capital Region, Denmark (H-KF-01- 131/03 and
addendum of June 2009). Written informed consent was obtained from
parents of all participants” (Holm et al., 2018). The study was con-
ducted in accordance with the Helsinki declaration.
2.2. Clinical characteristics
“Patients' medical charts were reviewed, and diagnosis and gluco-
corticoid treatment data were collected” (Holm et al., 2018). “The study
included 11 patients with nephrotic syndrome and 19 with rheumatic
disease. The group of children with nephrotic syndrome included
idiopathic nephrotic syndrome (n = 5), nephrotic syndrome associated
with Henoch-Schönlein purpura (n = 4), and nephrotic syndrome as-
sociated with glomerulonephritis (n = 2). The group of children with
rheumatic disease included systemic juvenile idiopathic arthritis (n =
1), polyarticular juvenile idiopathic arthritis (n = 3), oligoarticular
juvenile idiopathic arthritis (n = 8), enthesitis-related juvenile idio-
pathic arthritis (n = 2), juvenile dermatomyositis (n = 3), mixed
connective tissue disease (n=1), and systemic lupus erythematosus (n
= 1).” (Holm et al., 2018). Treatment variables are presented in
Table 2. “The primary treatment variable was cumulative prednisolone
equivalent glucocorticoid dose (mg/kg). In addition, median daily dose
(mg/kg/day), median treatment age, and time since treatment (i.e.,
time elapsed from treatment termination to assessment) were regis-
tered. Glucocorticoids were administered orally. However, ﬁve patients
(one with nephrotic syndrome and four with rheumatic disease) re-
ceived intravenous glucocorticoid high-dose therapy (pulse therapy) in
addition to oral glucocorticoid treatment, which constituted between
36 and 64% of their cumulative dose” (Holm et al., 2018). Twelve
patients received non-glucocorticoid treatment at the time of assess-
ment, which included TNF-α-inhibitors (n= 7), methotrexate (n= 3),
anti-hypertensive drugs (n=2), interleukin-1-inhibitor (n=1), and
non-steroid anti-inﬂammatory drugs (n= 1).
2.3. Background variables
“The assessment of background and cognitive variables are de-
scribed in detail elsewhere (Holm et al., 2015). Height, weight, head
circumference, and pubertal development (Tanner staging) were mea-
sured. Current and previous physical activity, stressful life events, and
behavioral problems were assessed by questionnaires” (Holm et al.,
2018). Verbal intellectual ability was estimated using the verbal com-
prehension index (VCI) based on the information and vocabulary
subtests from the Wechsler Intelligence Scale for Children III (Priﬁtera
and Saklofoske, 1998). Endogenous cortisol levels were measured by
collecting saliva samples using oral swabs (Salimetrics Oral Swab,
Salimetrics, Pennsylvania, USA) on two consecutive regular schooldays.
Measures of interest were CAR and daily cortisol levels assessed by
calculating area under the curve, both expressed as averages of the two
sample days. For a detailed description of how measures were calcu-
lated see (Vestergaard et al., 2017).
2.4. Image acquisition
Structural MRI of participants was obtained on a 3 T Siemens
Magnetom Trio magnetic resonance scanner (Siemens, Erlangen,
Germany) using an eight-channel head coil (Invivo, Florida, USA).
High-resolution whole brain 3D T1-weighted Magnetization Prepared
Rapid Gradient Echo (MPRAGE) images were acquired (TE=3.04ms,
TR=1550ms, matrix= 256×256mm, 192 sagittal slices, no gap,
1mm3 voxels). Whole brain DWI was acquired using a twice-refocused
balanced spin-echo sequence to minimize distortions by eddy currents
(Reese et al., 2003). We acquired 10 non-DW images (b= 0) and 61
DW images, which were encoded along independent collinear diﬀusion
gradient orientations (TR=8200ms, TE=100ms,
FOV=220×220mm2, matrix= 96×96, GRAPPA (GeneRalized
Autocalibrating Partial Parallel Acquisition): factor 2, 48 lines, 61
perpendicular slices, no gap, 2.3mm3 voxels). A gradient echo ﬁeld
map was obtained to correct for B0 ﬁeld distortions (Andersson et al.,
2001) (TR=530ms, TE[1]= 5.19ms and TE[2]=7.65ms,
FOV=256×256mm2, matrix= 128×128, 47 perpendicular slices
with no gap, 2×2×3mm3 voxels). Both the DWI and the gradient
ﬁeld map scans were oriented parallel to the anterior-posterior com-
missure line. All images were inspected for quality. All T1-weighted
images were evaluated by a neuroradiologist and deemed without
clinical pathology.
2.5. Image preprocessing
2.5.1. Preprocessing of T1-weighted images
T1-weighted images were processed using the VBM5.1 toolbox im-
plemented in SPM8 (www.ﬁl.ion.ucl.ac.uk/spm/software/spm8) run-
ning in Matlab R2013b. Initially, images were gradient unwarped to
correct for non-linear spatial distortions in the scanner gradients
(Jovicich et al., 2006). After a 6 parameter rigid transformation to MNI-
space, grey and white matter and CSF were segmented with VBM5.1
using default settings and the Hidden Markov Random Field method
(Cuadra et al., 2005). A brain mask generated using the graph-cut mask
function was applied to the segmented tissue images to remove extra-
cerebral tissue voxels. Tissue segmentations were visually inspected to
ensure quality before warping the grey and white matter images with
DARTEL (Diﬀeomorphic Anatomic Registration Through Exponentiated
Lie algebra) to achieve high-dimensional inter-individual alignment
(Ashburner, 2007). Subsequently, the individual DARTEL deformation
ﬂow ﬁelds were applied to individual masked brain tissue images in
order to bring them into a common “DARTEL” space.
2.5.2. Pre-processing of diﬀusion weighted images
DW images were pre-processed using pipelines implemented in
Matlab, using SPM8 routines as well as FSL 5.0.1 (http://www.fmrib.
ox.ac.uk/). For each individual, DW images were co-registered to the
average of all b0 images (no reslicing). Subsequently, DWI images were
corrected for geometric distortions due to B0 ﬁeld inhomogeneity and
gradient non-linearity (Andersson et al., 2001; Jovicich et al., 2006)
and transformed into MNI orientation (no scaling) using a single tri-
linear interpolation. The diﬀusion orientations were adjusted to ac-
count for any rotation applied during registration (Leemans and Jones,
2009). To exclude non-brain voxels DW images were masked with a
brain mask that was created by applying the Brain Extraction Tool
(BET) implemented in FSL (Smith, 2002) on each non-DW image and
taking the median of the resulting masks. The diﬀusion tensor was
ﬁtted using a least-squares-ﬁt by non-linear optimization employing a
Levenburg-Marquardt algorithm (Jones and Basser, 2004) and con-
strained to be positive deﬁnite by ﬁtting its Cholesky decomposition
implemented in Camino (Cook et al., 2006). Fractional anisotropy (FA)
and mean diﬀusivity (MD) images were calculated. MD was calculated
as the mean of diﬀusivities along three perpendicular axes (λ1, λ2, λ3)
(Basser and Jones, 2002). FA images were used to calculate the best
possible (non-linear) registration between MD images and individual
T1-weighted anatomical images as part of the procedure to extract in-
dividual ROI MD (see below).
2.5.3. Grey matter regions-of-interest
Participants' T1-weighted images were warped into “DARTEL”
space using individual DARTEL ﬂow ﬁelds. Next, resulting images were
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averaged to create a T1-weighted study template, on which grey matter
regions-of-interest (ROIs) were delineated using FSLView (www.fsl.
fmrib.ox.ac.uk/fsl/fslview). Using the inverse DARTEL ﬂow ﬁelds ROIs
were transformed into each individual's T1-weighted image native
space and edited to ensure their ﬁt while blinded to subject identity.
The left and right hippocampi and amygdalae were drawn using
previously described guidelines (Entis et al., 2012; Maller et al., 2006).
The hippocampal ROI included the cornu ammonis, dentate gyrus, al-
veus, and part of subiculum, while the ﬁmbria and parahippocampal
gyrus were excluded. For the striatal ROIs, striatal cell bridges were not
included. The accumbens was delineated on the ﬁrst axial slice where
the caudate nucleus and putamen joined inferiorly and was not allowed
to extend posteriorly beyond the anterior commissure. In coronal view,
the accumbens was separated from the caudate nucleus by a straight
line connecting the most inferior part of the frontal horn of the lateral
ventricle to the most inferior part of the internal capsule. The border
between accumbens and putamen was drawn as a straight vertical line
from the most inferior part of the internal capsule. The caudate nucleus
was delineated posteriorly until the posterior commissure. The ROIs are
shown in Fig. 1.
To extract individual ROI MD, we used the following procedure to
minimize white matter and CSF partial volume eﬀects and maximizing
sampling within grey matter tissue. Firstly, ROIs were eroded using a
1mm Gaussian kernel, thereby excluding an approximately one-voxel
thick layer from the outer border of the ROI. Secondly, for each in-
dividual, the FA image was warped to the T1-weighted image in native
space using the linear FLIRT and non-linear FNIRT registration algo-
rithms in FSL. The resulting deformation ﬁelds were then applied to the
MD images and the anatomical ﬁt was visually inspected. Thirdly, using
the inverse deformation the eroded ROIs residing in T1-weighted native
space were transformed to diﬀusion-weighted native image space using
tri-linear interpolation and binarized using a threshold of 0.5. The
anatomical match was visually inspected. Fourthly, the binary ROIs
were multiplied by the participant's perpendicular diﬀusivity image,
and then thresholded at a perpendicular diﬀusivity of< 0.0011, in
order to exclude any remaining CSF partial volume voxels. Finally,
mean MD values were extracted from the ﬁnal ROIs for each subject. To
estimate individual global MD within grey and white matter, mean MD
was calculated within a whole brain mask created by thresholding in-
dividual perpendicular diﬀusivity images< 0.0009 to exclude CSF and
CSF partial volume voxels.
To obtain estimates of total brain volume (TBV) for use in the sta-
tistical analyses, we used the automated calculated TBV within
FreeSurfer, a freely available software package for structural and
functional image analyses (https://surfer.nmr.mgh.harvard.edu).
Processing of individual T1-weighted images with FreeSurfer followed
standard procedures and is described in detail elsewhere (Holm et al.,
2018). The pial and grey-white matter surfaces generated by FreeSurfer
were visually inspected and corrected following standard guidelines
where necessary. The TBV included supra- and infratentorial volumes
of grey and white matter, while ventricles, brain-stem and choroid
plexus were excluded (www.freesurfer.net/fswiki/MorphometryStats).
2.6. Statistics
The statistical analyses for demographic and background variables
are largely the same as in our previous work (Holm et al., 2018).
Therefore, wherever information is the same it is presented between
quotation marks, followed by the reference to the article in which the
information can be found. SPSS 20 (SPSS, IBM Corp., USA) was used for
statistical analyses.
2.6.1. Demographic and background variables
“A χ2-test tested for possible gender diﬀerences. The Shapiro–Wilk
test was used to test whether continuous variable distributions deviated
from a normal distribution. Independent samples t-tests tested for group
diﬀerences in normally distributed variables, including age and parent
education. Group diﬀerences in the background, behavioral, and cog-
nitive variables, height, weight, head circumference, verbal compre-
hension index (VCI), perceptual organization index, Tanner stage,
physical activity, stressful life events, behavioral problems, and pattern
recognition memory were evaluated using multiple linear regression
with age and gender as control variables. The lifetime stressful life
event (SLE) questionnaire includes two statements regarding somatic
disease (i.e., “my child had a medical diagnosis” and “my child was
severely ill or injured”), which patients and controls are expected to
diﬀer on. Therefore, we report stressful life events with and without
these disease-related questions. Within patients, Mann–Whitney U tests
tested for potential gender- and disease-group diﬀerences in treatment
variables” (Holm et al., 2018). CAR and the daily cortisol levels were
evaluated using multiple linear regression with age and gender as
control variables.
2.6.2. Subcortical brain measures
Potential diﬀerences between patients and controls in ROI volume
or ROI MD were evaluated using multiple linear regression analyses. All
assumptions for linear regression were fulﬁlled. Adjusted mean diﬀer-
ences (AMD) are reported i.e. diﬀerence between groups in ROI vo-
lumes and ROI MD after controlling for all other predictors in the re-
gression model.
Our primary hypothesis was that patients would have smaller left
and right hippocampal and amygdala volumes compared to controls
and that this diﬀerence would be independent of previously observed
group diﬀerences in whole brain volume. Secondary, we expected that
patients as compared to controls would diﬀer in hippocampus and
amygdala MD. ROI volume or ROI MD were used as dependent
Fig. 1. Regions-of-interest.
Regions-of-interest overlaid on the average of warped T1-weighted images.
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variables, and group (controls versus patients), age and gender were
used as independent prediction variables. The anatomic speciﬁcity of
observed associations was assessed by adding TBV in models predicting
ROI volume, and global MD in models predicting ROI MD.
Hippocampus and amygdala volume and MD were analyzed uni-
laterally since study ﬁndings suggest lateralized relations between
glucocorticoids and limbic structures (Cerqueira et al., 2008; Madsen
et al., 2012). Bilateral measures were used for testing group diﬀerences
in putamen, caudate nucleus or nucleus accumbens volume or MD.
Finally, we explored group by gender interactions to evaluate potential
gender speciﬁc diﬀerences between patients and controls controlling
for age and global measures. Pertinent to a signiﬁcant interaction, we
tested group diﬀerences for each gender separately.
2.6.3. Associations with glucocorticoid treatment variables
Contingent on ﬁnding signiﬁcant group diﬀerences in ROI volume
or ROI MD, adjusted for global measures, we investigated for associa-
tions between ROI volume or ROI MD and treatment variables in pa-
tients, controlling for age, sex and global measure. First, we tested if
ROI volume or ROI MD was associated with cumulative glucocorticoid
dose. Second, we tested for associations with median daily dose,
treatment duration, median treatment age, or time since treatment.
Third, we tested for a cumulative dose by median treatment age in-
teraction, controlling for age, sex and global measure, cumulative dose,
median treatment age, and time since treatment. The cumulative dose
by median treatment age interaction tested whether the eﬀect of glu-
cocorticoid treatment diﬀered depending on the age at which children
received treatment.
2.6.4. Planned follow-up analyses
To evaluate if observed group diﬀerences were present in each of
the disease groups, we contrasted rheumatic disease patients and ne-
phrotic syndrome patients separately with healthy controls, controlling
for age, gender, and TBV or global MD.
Since patients had signiﬁcant lower VCI scores than controls (see
under results), we investigated the possible relationship between VCI
and those volume and MD measures for which controls and patients
signiﬁcantly diﬀered from each other. Firstly, VCI was predicted with
brain measure controlling for group, age, gender and global measure.
Secondly, we tested for possible group by VCI interactions on ROI vo-
lume and ROI MD, controlling group, age, gender, VCI and global
measure.
For the primary hypotheses concerning left and right hippocampal
and amygdala volume, we used a Bonferroni corrected p-value of 0.013
(α=0.05/4). Since this, to our knowledge, is the ﬁrst study to in-
vestigate the possible long-term impact of glucocorticoid treatment
during childhood on subcortical grey matter structures, we were
interested to identify potential group diﬀerences and associations that
can be tested in future studies. Therefore, in all subsequent analyses we
considered eﬀects with p-values lower than 0.05 of interest.
3. Results
Results on demographic data and background variables (except CAR
and daily cortisol levels) are the same as presented in our previous
article on global brain measures (Holm et al., 2018). These results will
be presented between quotation marks followed by the reference to the
previous article and the page at which the information can be found.
3.1. Missing data
There was missing data for measures of CAR and daily cortisol level
(one female patient with rheumatic disease), current physical activity
(two female patients with rheumatic disease and one male control),
previous physical activity (two female patients with rheumatic disease)
and DWI scans (two controls: one boy, one girl, and three female pa-
tients with rheumatic disease).
3.2. Demographic data and background variables
Demographic variables are presented in Table 1. Age, gender, and
parental education were not signiﬁcantly diﬀerent between controls
and all patients or between controls and the separate disease groups.
Furthermore, comparisons between the two patient groups revealed no
signiﬁcant diﬀerences in age (t=0.12, p= .91), gender (p= .08), or
parent education (t=0.54, p= .59).
“Patients had signiﬁcantly lower weight and height in comparison
with control. Head circumference, although lower, was not signiﬁcantly
diﬀerent between groups. In agreement with our ﬁndings in the larger
cohort, patients had signiﬁcantly lower VCI compared with that in the
controls, whereas there was no diﬀerence regarding the perceptual
organization index, memory performance, or behavioural problems
(Holm et al., 2015). Patients and controls did not signiﬁcantly diﬀer in
pubertal development, physical activity, or stressful life events in the
preceding year. In accordance with our previous ﬁndings in a larger
cohort (Holm et al., 2015), the number of stressful life events during the
child's entire lifetime was higher in patients compared with that in
controls; however, after exclusion of disease-related questions, this
diﬀerence was no longer present” (Holm et al., 2018, Table 2, page
807). Patients and controls did not signiﬁcantly diﬀer in CAR (Patients:
Mean (standard deviation (SD))= 0.33 (0.03); Controls: Mean
(SD)=0.30 (0.02); β=0.13, p= .36) or daily cortisol (in nmol/l/min;
Patients: Mean (SD)=4.01 (0.38); Controls: mean (SD)=3.87 (0.24);
β=0.02, p= .91).
Table 1
Demographic variables.
Controls All patients Nephrotic syndrome Rheumatic disease
(n=30) (n=30) (n=11) (n=19)
Gender (boys/girls) 11/19 8/22 5/6 3/16
p-Value NA p= .405 p= .609 p=.115
Age (years)
Mean (SD) 11.9 (2.4) 12.5 (2.2) 12.6 (2.2) 12.4 (2.3)
Range 7.0–15.6 7.0–16.1 8.2–16.1 7.0–15.6
p-Value NA t=−0.99, p=.327 t=−0.820, p= .417 t=−0.809, p= .424
Parental education (years)
Mean (SD) 14.5 (1.6) 14.0 (2.0) 14.25 (2.7) 13.8 (1.5)
Range 11.0–16.5 9.0–17.0 9.0–17.0 11.5–17.0
p-Value NA t=1.00, p= .320 t=0.282, p=.780 t=1.356, p= .182
SD= standard deviation. All p-values are derived from comparisons against controls. Gender diﬀerences were tested with Chi Square tests. Group diﬀerences in age
and parent education were tested with independent samples t-tests. Patients (n=27) and controls (n=28) for whom diﬀusion weighted images were obtained did
not diﬀer in age (t=−1.3, p= .19), gender (p= .63), or parental education (t=1.1, p= .29).
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3.3. Treatment variables
Treatment variables and the results of statistical analyses comparing
children with nephrotic syndrome with children with rheumatic disease
and comparing boys and girls are presented in Table 2. Children with
nephrotic syndrome received signiﬁcant higher cumulative dose and
median daily dose of glucocorticoids than children with rheumatic
disease. Disease groups did not diﬀer on any of the other treatment
variables. Additionally, patient boys had signiﬁcantly longer time since
treatment and received higher median daily doses than patient girls.
Boys and girls did not diﬀer in the remaining treatment variables.
Disease group by gender interaction eﬀects were absent (p-values>
.11).
3.4. Subcortical brain measures
Measures of ROI volume and ROI MD for controls and patients and
patient groups separately are presented in Table 3. Results of multiple
regression analyses of volume and MD are presented in Table 4 and
Table 5, respectively.
3.4.1. Primary analyses
3.4.1.1. Hippocampal and amygdala volume. Patients had smaller right
hippocampal volumes compared to controls (AMD=−153.3 mm3;
95% CI=−280 – -27). This diﬀerence was not statistically
signiﬁcant when correcting for multiple comparisons. (α=0.05/
4= 0.013). Nevertheless, we corrected for TBV to evaluate if smaller
hippocampal volumes would show some anatomical speciﬁcity i.e. if
the eﬀect remained or became more outspoken. However, neither was
the case (AMD=−102.8 mm3; 95% CI=−226–21). Groups did not
diﬀer in left hippocampal volume. We did not ﬁnd any signiﬁcant group
by gender interaction eﬀects (right: β=0.06, p= .63 and left:
β=0.10, p= .44).
Patients and controls did not signiﬁcantly diﬀer in left or right
amygdala volume without or with correction for TBV. There was some
indication for a group by gender interaction for both left (β=0.22,
p= .035) and right amygdala (β=0.19, p= .066) volumes. These
interactions were due to patient boys having smaller volumes than
healthy control boys, while patient and control girls did not diﬀer from
each other.
3.4.2. Secondary analyses
3.4.2.1. Hippocampal and amygdala MD. Patients had lower right
hippocampal MD as compared to controls (AMD=−9.3× 10−6 m2/
s; 95% CI=−18×10−6 to −0.3×10−6). This group diﬀerence
remained when controlling for global MD (AMD=−9.7× 10−6 m2/
s; 95% CI=−18×10−6 to −1×10−6; Fig. 2A). Patients and
controls did not statistically diﬀer in left hippocampal MD. Group by
gender interactions were absent (right hippocampus: β=0.23, p= .68,
left hippocampus: β=−0.06, p= .67).
Patients and controls did not signiﬁcantly diﬀer in left or right
amygdala MD without or with correction for global MD. Group by
gender interactions were absent (left amygdal: β=0.12, p= .39 and
right amygdala: β=0.15, p= .22).
3.5. Explorative analyses
3.5.1. Putamen, caudate nucleus and nucleus accumbens volume
Patients had signiﬁcantly smaller putamen volume as compared to
controls (AMD=−675mm3; 95% CI=−1091 to −259) and this
group diﬀerence remained after controlling for TBV
(AMD=−353mm3; 95% CI=−662 – -44; Fig. 2B). We did not ﬁnd a
signiﬁcant group by gender interaction (β=0.04, p= .69).
Patients and controls did not signiﬁcantly diﬀer in caudate nucleus
Table 2
Glucocorticoid treatment variables.
Treatment variables All patients Rheumatic disease Nephrotic syndrome p§ Girls Boys p#
Median treatment age years 7.0 (1.9–12.3) 6.9 1.9–12.3) 7.1 (4.5–10.5) .40 7.1 (1.9–12.3) 7.0 (5.1–9.8) .99
Cumulative dose mg/kg 157.8 (20.8–580.5) 102.8 (20.8–580.5) 298.8 (118.6–514.2) .03 146.6 (20.8–580.5) 237.5 (73.5–514.2) .50
Median daily dose mg/kg/day 0.2 (0.1–2.1) 0.2 (0.1–1.1) 0.6 (0.1–2.1) .03 0.2 (0.1–1.1) 0.6 (0.1–2.1) .05
Treatment duration years 1.0 (0.1–5.7) 1.1 (0.1–5.7) 0.8 (0.3–3.9) .50 0.8 (0.1–5.7) 1.1 (0.5–1.8) .95
Time since treatment years 4.0 (0.2–8.9) 3.6 (0.2–6.8) 4.6 (0.6–8.9) .55 3.4 (0.2–6.8) 5.0 (2.4–8.9) .02
Values are presented as median (range). Glucocorticoid treatment variables are expressed as prednisolone equivalents. Mann Whitney U tests were used to compare §
Rheumatic group versus Nephrotic group and # Girls versus Boys. P values< .05 are displayed in italic bold.
Table 3
Volume and MD for ROIs in controls, patients and the separate disease groups.
Measure Hemisphere Controls All patients Rheumatic disease Nephrotic syndrome
Hippocampal volume Right 2352 ± 276 2186 ± 196 2188 ± 212 2182 ± 176
Left 2265 ± 300 2181 ± 217 2178 ± 204 2214 ± 245
Hippocampal MD Right 903 ± 16 892 ± 18 893 ± 13 890 ± 24
Left 877 ± 17 872 ± 22 873 ± 22 870 ± 22
Amygdala volume Right 1234 ± 113 1193 ± 128 1190 ± 127 1198 ± 135
Left 1197 ± 110 1162 ± 109 1154 ± 115 1177 ± 101
Amygdala MD Right 839 ± 21 838 ± 16 837 ± 15 840 ± 17
Left 827 ± 23 821 ± 20 819 ± 21 823 ± 19
Putamen volume Bilateral 8721 ± 808 8156 ± 695 8053 ± 607 8305 ± 814
Putamen MD 797 ± 13 793 ± 16 778 ± 16 801 ± 14
Caudate nucleus volume Bilateral 7637 ± 920 7404 ± 844 7282 ± 684 7582 ± 1045
Caudate nucleus MD 798 ± 22 793 ± 19 786 ± 16 802 ± 20
Accumbens volume Bilateral 505 ± 61 493 ± 58 490 ± 47 498 ± 74
Accumbens MD 835 ± 20 831 ± 30 810 ± 32 837 ± 27
Total brain volume (cm3) NA 1264 ± 108 1201 ± 104 1185 ± 112 1230 ± 88
Whole brain MD NA 800 ± 16 796 ± 14 792 ± 11 801 ± 15
MD: mean diﬀusivity. Values are mean ± standard deviation. Volumes are given as mm3 if not stated otherwise and MD is given as 10−6 m2/s. Volume measures
included 30 controls, 19 patients with rheumatic disease, and 11 with nephrotic syndrome. MD measures included 28 controls, 16 patients with rheumatic disease,
and 11 with nephrotic syndrome.
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or nucleus accumbens volumes with or without correction for TBV.
Likewise, no signiﬁcant group by gender interactions were observed
(caudate nucleus: β=−0.07, p= .46; nucleus accumbens: β=0.02,
p= .90).
3.5.2. Putamen, caudate nucleus and nucleus accumbens MD
Patients and controls did not signiﬁcantly diﬀer in putamen, cau-
date nucleus or nucleus accumbens MD. We did not ﬁnd any signiﬁcant
group by gender interactions (putamen: β=0.004, p= .97, caudate
nucleus: β=0.05, p= .63; nucleus accumbens: β=0.12, p= .38).
3.6. Planned follow-up analyses
3.6.1. Right hippocampal MD
3.6.1.1. Associations with glucocorticoid treatment variables within
patients. Within patients, right hippocampal MD was not signiﬁcantly
associated with cumulative dose (β=−0.27, p= .17). However, we
found a positive association between right hippocampal MD and the
time elapsed since termination of treatment (β=0.57, p= .016,
Fig. 3A), suggesting that the longer time since patients received
glucocorticoids the more they resembled the control group. Median
daily dose, treatment duration, median treatment age, or the
cumulative dose by median treatment age interaction were not
signiﬁcantly associated with right hippocampal MD (p's > 0.1).
Excluding the ﬁve individuals who received pulse therapy did not
aﬀect the above ﬁndings.
3.6.1.2. Comparing disease groups separately to healthy controls. Follow-
up analyses investigating for group diﬀerences in right hippocampal
MD for each disease group separately, controlling for age, gender and
Table 4
Results for multiple regression analyses of ROI volume.
ROI Model Group Age Gender TBV
R2adj F p β p β p β p β p
Right hippocampus 1 0.09 3.0 .04 −0.31 .018a −0.05 .69 −0.17 .19
2 0.2 4.7 .003 −0.21 .10 −0.08 .50 −0.08 .54 0.37 .005
Left hippocampus 1 −0.02 0.62 .60 −0.15 .28 0.09 .51 −0.06 .67
2 0.15 3.61 .01 −0.02 .87 0.5 .68 0.06 .65 0.46 .001
Right amygdala 1 0.05 2.11 .11 −0.15 .24 0.08 .56 −0.25 .06
2 0.45 12.93 2*10−7 0.03 .76 0.02 .84 −0.08 .44 0.68 4*10−8
Left amygdala 1 0.06 2.12 .10 −0.16 .22 0.16 .20 −0.21 .12
2 0.43 11.91 5*10−7 0.02 .84 0.11 .27 −0.04 .69 0.65 1*10−7
Putamen 1 0.17 5.15 .003 −0.39 .002b −0.04 .74 −0.21 .09
2 0.58 21.37 5*10−10 −0.20 .026c −0.10 .27 −0.04 .70 0.68 8*10−10
Caudate nucleus 1 0.00 1.00 .40 −0.20 .128 −0.06 .64 0.05 .68
2 0.58 21.53 10*10−11 0.02 .84 −0.13 .14 0.26 .005 0.81 3*10−12
Nucleus accumbens 1 0.03 1.59 .20 −0.13 .31 −0.05 .70 −0.23 .08
2 0.29 7.06 .0001 0.02 .87 −0.10 .40 −0.09 .44 0.56 2*10−5
In models 1 (Degrees of freedom: = 3, 56), group, age and gender were used as independent variables. In models 2 (Degrees of freedom=4, 55), group, age, gender
and total brain volume (TBV) were used as independent variables. Negative β- values reﬂect lower volume in patients compared to controls or lower volume in girls
compared to boys. Analyses included 30 patients and 30 controls. ROI=Region-of-interest. R2adj=adjusted R-squared. P values< .05 are displayed in italic bold.
Eﬀect sizes are expressed as squared semi-partial correlations (Sr2), which represent the proportion of the outcome variance that is associated uniquely with the
predictor.
a Sr2(model 1, right hippocampus, group)= 0.09.
b Sr2(model 1, putamen, group) = 0.15.
c Sr2(model 2, putamen, group)= 0.04.
Table 5
Results for multiple regression analyses of ROI mean diﬀusivity (MD).
ROI Model Group Age Gender TBV
R2adj F p β p β p β p β p
Right hippocampus 1 0.16 4.49 .007 −0.26 .044a −0.32 .015 −0.10 .42
2 0.24 5.35 .001 −0.28 .027b −0.02 .90 0.08 .52 0.42 .014
Left hippocampus 1 0.07 2.45 .07 −0.8 .57 −0.33 .016 −0.01 .96
2 0.10 2.51 .05 −0.08 .53 −0.13 .48 0.01 .95 0.29 .12
Right amygdala 1 0.32 9.54 4*10−5 0.11 .36 −0.61 3*10−6 −0.18 .12
2 0.33 7.60 7*10−5 0.10 .39 −0.47 .005 −0.17 .14 0.19 .23
Left amygdala 1 0.20 4.27 .009 −0.08 .54 −0.34 .011 −0.30 .021
2 0.15 3.31 .018 −0.08 .53 −0.25 .17 −0.29 .026 0.13 .47
Putamen 1 0.03 1.56 .21 −0.12 .38 −0.22 .12 0.10 .47
2 0.45 11.96 7*10−7 0.15 .16 0.42 .006 0.15 .15 0.89 1*10−7
Caudate nucleus 1 0.21 5.80 .002 −0.05 .67 −0.47 .0004 0.12 .35
2 0.44 11.68 9*10−7 −0.07 .50 0.01 .95 0.15 .14 0.67 2*10−5
Nucleus accumbens 1 −0.03 0.54 .66 −0.06 .68 −0.12 .40 0.09 .52
2 0.12 2.92 .030 −0.07 .58 0.27 .14 0.12 .35 0.56 .003
In models 1(Degrees of freedom: = 3, 56), group, age and gender were used as independent variables. In models 2 (Degrees of freedom: = 3, 56), group, age, gender
and global MD were used as independent variables. Negative β-values reﬂect lower MD in patients compared to controls or lower MD in girls compared to boys.
Analyses included 28 controls and 27 patients. ROI=Region-of-interest, M=Model, R=Right, L= Left. P values< .05 are displayed in italic bold. Eﬀect sizes are
expressed as squared semi-partial correlations (Sr2), which represent the proportion of the outcome variance that is associated uniquely with the predictor.
a Sr2(model 1, right hippocampus, group)= 0.07.
b Sr2(model 2, right hippocampus, group) = 0.07.
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global MD, revealed that children with nephrotic syndrome
(β=−0.39; p= .005; AMD=−16.4× 10−6; 95%
CI=−27×10−6 to −5×10−6) but not children with rheumatic
disease (β=−0.17; p= .23; AMD=−2.8×10−6; 95%
CI=−7×10−6–2× 10−6) showed lower right hippocampal MD as
compared to controls. Nevertheless, the observed positive association
between time since treatment and right hippocampal MD was present in
both patient groups (nephrotic syndrome: β=0.48, p= .052 and
rheumatic disease: β=0.58, p= .059).
3.6.1.3. Associations with verbal comprehension index. VCI was still
signiﬁcantly lower in patients than controls after controlling for right
hippocampal MD, and there was no apparent association between right
hippocampal MD and VCI (Group: β=−0.46, p= .001; Right
hippocampal MD: β=0.13, p= .38; Age: β=0.17, p= .33; Gender:
β=0.05, p= .67; Global MD: β=−0.02, p= .91). Moreover, we
found no signiﬁcant group by VCI interaction eﬀect on right
hippocampal MD (β=0.41, p= .36).
3.6.2. Putamen volume
3.6.2.1. Associations with glucocorticoid treatment variables within
patients. Putamen volume was not associated with cumulative dose
(β=−0.19, p= .14), median daily dose, treatment duration, nor time
since treatment (p's > 0.26). However, putamen volume was
negatively associated with median treatment age (β=−0.31,
p= .03; Fig. 3B). Putamen volume was not associated with
cumulative dose by median treatment age (p > .7). Excluding
individuals who received pulse therapy did not aﬀect the above
ﬁndings.
3.6.2.2. Comparing disease groups separately to healthy controls. Analyses
revealed that the observed group diﬀerence in putamen volume was
present in children with rheumatic disease (β=−0.25; p= .02;
AMD=−446mm3; 95% CI=−818 – -74), but not in children with
nephrotic syndrome (β=−0.13; p= .26; AMD=−247mm3; 95%
CI=−686–193). Furthermore, the observed negative association
between median treatment age and putamen volume was present in
the children with rheumatic disease (β=−0.44, p= .015), while
absent in children with nephrotic disease (β=0.08, p= .84).
3.6.2.3. Associations with verbal comprehension index. VCI was still
signiﬁcantly lower in patients than controls after controlling for
putamen volume, and there was no apparent relationship between
putamen volume and VCI (Group: β=−0.48, p= .0004; Putamen
volume: β=0.07, p= .70; Age: β=0.22, p= .07; Gender: β=0.06,
p= .63; TBV; β=0.18, p= .30). There was no group by VCI
Fig. 2. Group diﬀerences in ROI MD and volume.
Partial regression plots for diﬀerences between controls and patients in (A) right hippocampal mean diﬀusivity adjusted for age, gender and global MD, and (B)
bilateral putamen volume adjusted for age, gender and total brain volume. The horizontal dashed lines represent the group mean. MD: mean diﬀusivity. Note that the
partial regression plots display the model residuals and thus render values arbitrary.
Fig. 3. Associations between treatment variables and ROI MD and volume.
Partial regression plots with solid lines representing the linear model slope and dashed lines representing the 95% conﬁdence intervals. A) Association between right
hippocampal MD and the time elapsed since termination of glucocorticoid treatment, adjusted for age, gender, and global MD. B) Association between putamen
volume and the median treatment age adjusted for age, gender, and total brain volume. Note that the partial regression plots render values to be arbitrary.
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interaction (β=−0.01, p= .99).
4. Discussion
To the best of our knowledge the present study is the ﬁrst to de-
scribe a possible relationship between extra-cerebral diseases treated
with glucocorticoids during childhood and adolescence, and diﬀerences
in limbic and striatal grey matter structure volume and microstructure
in children and adolescents. Contrary to our expectations, patients did
not diﬀer from controls in hippocampal or amygdala volumes, as the
initially observed smaller right hippocampal volumes in patients as
compared to healthy did not survive correction for multiple compar-
isons. Furthermore, exploring if the uncorrected group diﬀerence
showed anatomical speciﬁcity, by correcting for TBV, revealed this
likely not to be the case. Nevertheless, patients displayed lower right
hippocampal MD than healthy controls, a diﬀerence that remained
when accounting for whole brain MD. Although lower right hippo-
campal MD was most prominent in children with nephrotic syndrome,
who had received the highest cumulative and median daily gluco-
corticoid dose, possible disease-speciﬁc eﬀects cannot be excluded.
Interestingly, we found that the right hippocampal MD in patients
reached values comparable to those of healthy controls the more time
had elapsed since glucocorticoid treatment. This relationship was ob-
served in both disease groups separately. Patients did not diﬀer from
controls in amygdalae MD. Finally, putamen volume was smaller in
patients as compared to controls, a diﬀerence that was mainly driven by
the children with rheumatic disease. Notably, putamen volume was
smaller the older the children were when receiving glucocorticoid
treatment.
The general lack of studies investigating the eﬀect of glucocorticoid
treatment in childhood and adolescence for extra-cerebral diseases on
limbic and striatal grey matter structures makes it diﬃcult to assess the
validity and signiﬁcance of our ﬁndings. Our observation of smaller
right hippocampal volumes in patients as compared to healthy controls
did not survive correction for multiple comparisons. Exploring if this
diﬀerence might show anatomical speciﬁcity, by correcting for TBV,
revealed that this likely was not the case. The latter would align with
our previous ﬁnding in the same cohort with patients displaying sig-
niﬁcant smaller total brain volumes as compared to healthy controls
(Holm et al., 2018). Overall, our failure to observe hippocampal volume
diﬀerences may be rooted in e.g. insuﬃcient statistical power, lack of
anatomical speciﬁcity, and/or a lack of signal in hippocampal volume
due to relatively low median daily glucocorticoid doses in combination
with relative lengthy time since treatment. Nevertheless, our observa-
tion warrants further investigation given the available evidence sug-
gesting that postnatal treatment with glucocorticoids aﬀects hippo-
campal volume. In a study of preterm born children (gestational age at
birth< 30weeks), scanned at term-equivalent age (38–42weeks'
postmenstrual age), postnatal exposure to glucocorticoids was found to
predict smaller right and left hippocampal volumes corrected for in-
tracranial volume (Thompson et al., 2008). Moreover, adult patients
with asthma or rheumatic diseases receiving long-term glucocorticoid
treatment had smaller hippocampal volumes bilaterally as compared to
patients with asthma or rheumatic diseases with minimal lifetime cor-
ticosteroid exposure (Brown et al., 2004). However, it is not clear
whether this diﬀerence in volume is anatomically speciﬁc since the
authors did not correct for either intracranial volume or TBV. Fur-
thermore, in a recent study it was found that adult women treated with
glucocorticoids due to congenital adrenal hyperplasia (CAH) had lower
right hippocampal volumes (as well as smaller volumes in left and right
thalami, cerebellum, and brainstem), corrected for TBV, as compared to
healthy controls (Webb et al., 2018).
Our ﬁnding of lower right hippocampal MD in children previously
treated with glucocorticoids compared to healthy controls seems to
contrast with a recent report of increased MD in hippocampus as well as
in multiple white matter ﬁber tracts, uncorrected for whole brain tissue
MD, in women treated with glucocorticoids for CAH (Webb et al.,
2018). However, studies are diﬃcult to compare given the diﬀerences
in stage of development, the type of disease studied, demographic
characteristics of the study populations, and the applied methodologies.
Grey matter MD is thought to be aﬀected by cell density as in studies of
tumour tissue lower MD was related to higher cell density (Beaulieu,
2009; Chenevert et al., 2006; Gibbs et al., 2009). This suggests that
lower right hippocampal MD in children previously treated with glu-
cocorticoids may reﬂect an increase in the number of cellular elements.
Such an interpretation, however, seems counter-intuitive given gluco-
corticoids' known anti-proliferative eﬀects (Kino, 2015; Numakawa
et al., 2017). Furthermore, in a MR-spectroscopy study lower hippo-
campal N-acetyl aspartate ratio, representative of lower hippocampal
neural cell densities, was observed in adults chronically treated with
glucocorticoids for extra-cerebral diseases (Brown et al., 2004). More-
over, in animal models of perinatal glucocorticoid treatment, reduced
neurogenesis occurred both shortly after the exposure as well as in the
long-term (Kanagawa et al., 2006; Noorlander et al., 2008). Neuron
density, however, is not the only factor that can inﬂuence tissue MD.
Factors such as level of myelination, cell sizes, number of dendrites,
number of glial cells, inﬂammation or extracellular properties also play
a role (Alexander et al., 2007; Beaulieu, 2002). Although speculatively,
our ﬁnding of lower right hippocampal MD but not lower hippocampal
volumes, may well reﬂect an increase in the number of glia cells (Chetty
et al., 2014). In support for this notion, a MR-spectroscopy study in
adults with previously elevated endogenous glucocorticoid levels, due
to Cushing's syndrome, reported lower hippocampal N-acetyl aspartate
and higher glutamate and glutamine levels, suggestive of respectively
reduced neuronal density and increased glial proliferation (Resmini
et al., 2013). Our observation that right hippocampal MD became more
similar to that of healthy controls the more time had elapsed after
termination of glucocorticoid treatment, suggests that this eﬀect is, at
least partly, reversible. The functional implications of our ﬁndings re-
main to be clariﬁed. Since lower right hippocampal MD was more
prominent in children with nephrotic syndrome than in those with
rheumatic disease, we cannot rule out disease-speciﬁc eﬀects. However,
compared to the rheumatic group, the children with nephrotic syn-
drome had generally received higher glucocorticoid doses and the as-
sociation between right hippocampal MD and time since glucocorticoid
treatment was present in both disease-groups separately.
Given the widespread distribution of the glucocorticoid receptor
throughout the brain (Cao-Lei et al., 2013) and its aﬃnity of exogenous
glucocorticoids such as prednisolone, we also investigated for possible
group diﬀerences in striatal grey matter structures. Children previously
treated with glucocorticoids had signiﬁcantly smaller putamen volumes
than healthy controls. Although preliminary, this ﬁnding seems to align
with ﬁndings of a recent study of preterm born children treated with
dexamethasone in neonatal life, who had smaller caudate nucleus and
putamen volumes, as compared to preterm born children, who had not
received dexamethasone treatment, 18 years after exposure (Cheong
et al., 2014). Moreover, a study in preterm fetal sheep found that ex-
posure to glucocorticoids aggravated the neuronal injury following
asphyxia in the hippocampus, but also in the putamen (Koome et al.,
2013). However, smaller putamen volumes were most prominent in
children with rheumatic diseases and the observed negative association
between the median treatment age and putamen volume was absent in
the children with nephrotic disorder. Since the children with rheumatic
disease received lower cumulative and median daily dose of gluco-
corticoids than the children with nephrotic syndrome, our ﬁndings
suggest that the observed smaller putamen volume may more likely be
a disease-speciﬁc eﬀect rather than due to the glucocorticoid treatment
by itself. Furthermore, we may have lacked the statistical power to ﬁnd
smaller putamen volumes in patients with nephrotic syndrome given
the lower number of patients with nephrotic syndrome in our study.
Finally, it might also be that potential disease-speciﬁc ﬁndings are, at
least partly, reﬂective of an uneven gender distribution in the two
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disease groups, with more girls among the children with rheumatic
disease.
Overall, the present study is limited due to the relatively small
sample sizes, as well as an uneven gender distribution in the two dis-
ease groups, with more girls among the children with rheumatic dis-
ease. Thus, we cannot exclude if the lack of speciﬁc hippocampal vo-
lume diﬀerences is due to a lack of statistical power. Moreover, by the
very nature of our cross-sectional design we are not able to infer
causality of previous glucocorticoid treatment, nor are we able to infer
possible disease-related mechanism. Unfortunately, this inability to
diﬀerentiate disease-speciﬁc eﬀects from glucocorticoid treatment ef-
fects befalls most cross-sectional studies in patient populations.
Furthermore, some participants also received other drugs such as TNFα-
inhibitors or methotrexate. The most dominant non-glucocorticoid
treatment at the time of assessment concerned TNFα-inhibitors.
Interestingly, these have recently been found to prevent pharmacolo-
gical neurotoxicity in the developing brain in rodents (Chen et al.,
2016). Unfortunately, given the small number of patients receiving
additional drug treatment, we were not able to address this issue in the
current study and therefore cannot exclude the possibility that addi-
tional treatments may have inﬂuenced our results. Finally, an ideal
control group would consist of patients with comparable disease his-
tories, who had not been treated with glucocorticoids. However, it not
possible to identify such a disease control group due to diﬀerences in
disease mechanisms, course of illness, illness severity, and treatment.
By including the two non-cerebral disease groups, we reasoned that
eﬀects common to both groups, speciﬁcally associations with gluco-
corticoid treatment variables, would be more reﬂective of glucocorti-
coid treatment than disease-speciﬁc eﬀects.
In conclusion, we revealed for the ﬁrst time that extra-cerebral
diseases during childhood treated with glucocorticoids may be asso-
ciated with reduced subcortical grey matter volumes and lower right
hippocampal mean diﬀusivity later in life. While our results should be
considered preliminary, they warrant replication and elaboration in
larger, preferably prospective and longitudinal studies. Such studies
would also allow disentangling disease-speciﬁc eﬀects from gluco-
corticoid treatment eﬀects.
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